Janux Therapeutics, INC Form 4 insider transactions

David Alan Campbell, President and CEO and a Director of Janux Therapeutics, Inc., reported a transaction in 123,840 shares of common stock on July 31, 2026.

Janux Therapeutics President and CEO David Alan Campbell acquired 7,000 shares of common stock.

RA Capital Management reports a grant of restricted stock units and stock options to Dr. Jake Simson for his service on the Janux Therapeutics board.

Director Jake Simson was granted 5,500 restricted stock units and 15,500 stock options as part of standard compensation.

Janux Therapeutics director Winston Kung was granted 5,500 restricted stock units and 15,500 stock options on June 11, 2026.

Director Natasha Hernday was granted 5,500 restricted stock units and 15,500 stock options by Janux Therapeutics.

Director Eric Dobmeier was granted 5,500 restricted stock units and 15,500 stock options by Janux Therapeutics.

Director Vickie L. Capps was granted 5,500 restricted stock units and 15,500 stock options by Janux Therapeutics, Inc.

Director Ronald W. Barrett was granted 5,500 restricted stock units and 15,500 stock options by Janux Therapeutics.

Chief Corporate & Business Development Officer Janeen Noel Doyle sold 4,059 shares of Janux Therapeutics to cover tax obligations.

Maria Dobek, Vice President of Accounting at Janux Therapeutics, sold 2,038 shares of common stock on May 11, 2026.

Janux Therapeutics' Chief Medical Officer, William Go, was granted 44,000 restricted stock units and options for 154,000 shares.

Janux Therapeutics' Chief Business Officer, Andrew Hollman Meyer, sold 1,879 shares of common stock to cover tax withholding obligations related to RSU vesting.

Janux Therapeutics' Chief Scientific Officer, Thomas DiRaimondo, reported recent stock sales for tax obligations, a significant RSU grant, and new stock option awards.

Janux Therapeutics CEO David Alan Campbell reported the sale of shares for tax obligations and the grant of new restricted stock units and stock options.

Janux Therapeutics' Chief Technical Officer, Charles M. Winter, reported the sale of shares for tax obligations and the acquisition of new restricted stock units and stock options.

Janux Therapeutics' Chief Medical Officer, Zachariah McIver, reported the sale of shares for tax obligations and the grant of new restricted stock units and stock options.

Janux Therapeutics' Chief Corporate and Business Development Officer, Janeen Noel Doyle, received significant equity grants, including restricted stock units and stock options.

Janux Therapeutics' VP of Accounting, Maria Dobek, reported the sale of shares for tax obligations, a new RSU grant, and a stock option grant.

Janux Therapeutics' Chief Business Officer, Andrew Hollman Meyer, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged trading plan.

Janux Therapeutics' Chief Business Officer, Andrew Hollman Meyer, exercised stock options and sold a portion of the resulting common stock under a pre-arranged 10b5-1 trading plan.

Janux Therapeutics' Chief Business Officer, Andrew Hollman Meyer, sold 16,665 shares of common stock for over $30 per share after exercising stock options.

RA Capital Management and its affiliated funds, along with key personnel, filed a Form 4 detailing the grant of restricted stock units and stock options to Dr. Jake Simson, a director of Janux Therapeutics, Inc., with beneficial ownership disclaimed by the reporting entities.

Janux Therapeutics, Inc. Director Ronald W. Barrett was granted 3,750 restricted stock units and options to purchase 11,667 shares of common stock on June 11, 2025, as part of his compensation.

Vickie L. Capps, a Director at Janux Therapeutics, Inc., was granted 3,750 Restricted Stock Units and options to purchase 11,667 shares of common stock on June 11, 2025.

Janux Therapeutics, Inc. Director Eric Dobmeier was granted 3,750 restricted stock units and options to purchase 11,667 shares of common stock, aligning his compensation with shareholder value.

Janux Therapeutics, Inc. Director Sheila Gujrathi was granted 3,750 restricted stock units and options to purchase 11,667 shares of common stock, aligning her interests with shareholders.

Janux Therapeutics, Inc. Director Natasha Hernday reported the acquisition of 3,750 restricted stock units and 11,667 stock options on June 11, 2025, as part of her compensation.

Janux Therapeutics, Inc. Director Alana B. McNulty was granted 3,750 restricted stock units and options to purchase 11,667 shares of common stock on June 11, 2025, as part of her compensation.

Janux Therapeutics Director Jake Simson reported the grant of 3,750 restricted stock units and 11,667 stock options, which he holds for the benefit of RA Capital Management funds, disclaiming personal beneficial ownership.